Joel R. Hecht, MD

Articles by Joel R. Hecht, MD

Dr Hecht on Barriers to Enrollment into the BASECAMP-1 Study in Solid Tumors

September 26th 2023

J. Randolph (Randy) Hecht, MD, discusses barriers to enrollment in the observational BASECAMP-1 study and the phase 1/2 EVEREST-1 study, which will investigate HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in patients with solid tumors.

Dr Hecht on the Investigation of the Novel CAR T-Cell Therapy A2B530 in Solid Tumors

ByJoel R. Hecht, MD

September 25th 2023

J. Randolph (Randy) Hecht, MD, discusses the observational BASECAMP-1 study and the investigation of HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in the phase 1/2 EVEREST-1 study, which will investigate A2B530 in patients with solid tumors.

Dr Hecht on Barriers to CAR T-Cell Therapy Treatment in Solid Tumors

ByJoel R. Hecht, MD

September 22nd 2023

J. Randolph (Randy) Hecht, MD, discusses barriers to treatment with CAR T-cell therapy in patients with solid tumors, highlighting various efforts that investigators are spearheading to address these unmet needs.

Dr Hecht on the Investigation of A2B530 in Germline HLA-A*02 Heterozygous Solid Tumors

ByJoel R. Hecht, MD

May 9th 2023

J. Randolph Hecht, MD, discusses the investigation of A2B530 in germline HLA-A*02 heterozygous solid tumors.

Metastatic Colorectal Cancer: Future Directions in Care

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

April 3rd 2023

Expert panelists identify key takeaways and share their excitement for future directions in the management of metastatic colorectal cancer.

Novel Combination Strategies in mCRC: The STELLAR-303 and SUNLIGHT Trials

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

March 27th 2023

Before closing out their review of combination therapy in metastatic colorectal cancer, panelists discuss the STELLAR-303 and SUNLIGHT clinical trials.

Combination IO/TKI Strategies in Metastatic Colorectal Cancer

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

March 27th 2023

A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer.

Clinical Trials in Metastatic Colorectal Cancer: Combination IO Therapy

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

March 20th 2023

A focused discussion on combination strategies with immune checkpoint inhibitors in patients with metastatic colorectal cancer.

Overview of Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

March 20th 2023

Switching their focus to immune checkpoint inhibitors, panelists provide an overview on the role of immunotherapy in metastatic colorectal cancer.

Other Combination Strategies in BRAF-Mutated Metastatic Colorectal Cancer

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

March 13th 2023

Before closing out their discussion on BRAF-mutated metastatic colorectal cancer, panelists consider other novel combination strategies in this setting.

Combination Therapy in BRAF-Mutated mCRC: The BREAKWATER Trial

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

March 13th 2023

Shared insight on the BREAKWATER trial, which combined encorafenib, cetuximab, and chemotherapy in patients with BRAF V600E–mutated metastatic colorectal cancer.

Combination Therapy in BRAF-Mutated mCRC: The BEACON CRC Trial

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

March 6th 2023

Expert perspectives on the BEACON CRC trial, which combined encorafenib, cetuximab, and binimetinib in patients with BRAF V600E–mutated metastatic colorectal cancer.

Importance of Identifying HER2 Status in Metastatic Colorectal Cancer

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

March 6th 2023

Following its discussion on trastuzumab deruxtecan and tucatinib therapy in HER2+ mCRC, the panel emphasizes the importance HER2 status identification in metastatic colorectal cancer.

Role of Tucatinib in HER2+ mCRC

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 27th 2023

Switching their focus to tucatinib, expert panelists review data from the MOUNTAINEER study and define the role of tucatinib in managing HER2+ metastatic colorectal cancer.

HER2+ mCRC: Managing Adverse Events Associated With Antibody Drug Conjugates

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 27th 2023

Comprehensive insight on the adverse event profile of antibody drug conjugate therapy as it compares to other agents in HER2+ metastatic colorectal cancer management.

Trastuzumab Deruxtecan in HER2+ mCRC

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 20th 2023

Centering discussion on clinical trials and experience with trastuzumab deruxtecan, expert oncologists identify its value in the HER2+ treatment landscape.

First-Line Treatment Options for mCRC

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 20th 2023

After a brief overview on first-line treatment options for patients with metastatic colorectal cancer, panelists highlight the role HER2 status plays in the selection of novel therapies.

Challenges With Molecular Testing in Metastatic Colorectal Cancer

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 16th 2023

A comprehensive discussion on the barriers to molecular testing in metastatic colorectal cancer, along with challenges in utilizing these tests in the real-world setting.

Circulating Tumor DNA to Guide Treatment Selection for mCRC

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 16th 2023

Panelists consider the potential role for circulating tumor DNA to inform the selection of therapy for patients with metastatic colorectal cancer.

Role of Tissue Versus Circulating Tumor DNA in Molecular Testing in mCRC

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 9th 2023

Shared insight on the value tissue and circulating tumor DNA respectively provide in molecular testing for patients with metastatic colorectal cancer.

Overview of Molecular Testing in Metastatic Colorectal Cancer (mCRC)

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Pashtoon M. Kasi, MBBS, MD, MS,Kanwal Raghav, MD,Joel R. Hecht, MD

February 9th 2023

Experts in metastatic colorectal cancer management highlight the role of molecular testing and testing modalities available in the academic and community settings.